Comparative Pharmacology
Head-to-head clinical analysis: ADMELOG SOLOSTAR versus NOVOLIN R.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADMELOG SOLOSTAR versus NOVOLIN R.
ADMELOG SOLOSTAR vs NOVOLIN R
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro, a rapid-acting insulin analog, lowers blood glucose by binding to and activating the insulin receptor, leading to increased glucose uptake in peripheral tissues (e.g., skeletal muscle, fat) and suppression of hepatic glucose production.
Regular insulin lowers blood glucose by promoting peripheral glucose uptake, especially in skeletal muscle and adipose tissue, and by inhibiting hepatic glucose production. It binds to insulin receptors on cell membranes, activating tyrosine kinase activity and downstream signaling pathways that regulate glucose transport and metabolism.
Subcutaneous injection starting dose 0.2-0.4 units/kg/day divided into 1-2 injections, or 0.1-0.2 units/kg/meal for prandial coverage; typical total daily dose 0.5-1.0 units/kg.
Subcutaneous: 0.5-1 unit/kg/day divided into 2-3 doses; intravenous: continuous infusion starting at 0.05-0.1 units/kg/hr adjusted based on blood glucose.
None Documented
None Documented
Terminal elimination half-life: 5-6 hours for insulin lispro; clinical context: reflects duration of glucose-lowering effect, allowing dosing before meals.
Intravenous: 5-10 minutes (short due to rapid distribution and degradation). Subcutaneous: 1-2 hours (terminal half-life after absorption).
Renal: 30-80% of dose excreted unchanged in urine; biliary/fecal: negligible.
Renal (tubular reabsorption and metabolism). Approximately 50-80% of insulin is degraded in the liver and kidneys; the remainder is excreted in urine as metabolites and intact hormone (<1%).
Category C
Category C
Insulin
Insulin